ProNAi Therapeutics, Inc. (NASDAQ:SRRA) – Jefferies Group issued their Q3 2017 earnings estimates for shares of ProNAi Therapeutics in a report released on Monday. Jefferies Group analyst M. Raycroft anticipates that the biotechnology company will post earnings of ($0.20) per share for the quarter. Jefferies Group has a “Buy” rating on the stock. Jefferies Group also issued estimates for ProNAi Therapeutics’ Q4 2017 earnings at ($0.21) EPS, FY2017 earnings at ($0.86) EPS, FY2018 earnings at ($0.72) EPS, FY2019 earnings at ($0.81) EPS and FY2020 earnings at ($0.81) EPS.

Several other brokerages also recently weighed in on SRRA. ValuEngine upgraded ProNAi Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st. Zacks Investment Research raised ProNAi Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, July 12th. One analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $4.00.

COPYRIGHT VIOLATION NOTICE: “ProNAi Therapeutics, Inc. (SRRA) Forecasted to Earn Q3 2017 Earnings of ($0.20) Per Share” was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this article on another publication, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/10/25/pronai-therapeutics-inc-srra-forecasted-to-earn-q3-2017-earnings-of-0-20-per-share.html.

Shares of ProNAi Therapeutics (SRRA) opened at 1.90 on Wednesday. The firm’s market cap is $99.31 million. The firm’s 50-day moving average is $1.65 and its 200-day moving average is $1.42. ProNAi Therapeutics has a 52-week low of $1.10 and a 52-week high of $1.94.

ProNAi Therapeutics (NASDAQ:SRRA) last released its earnings results on Thursday, August 10th. The biotechnology company reported ($0.20) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.01.

A hedge fund recently bought a new stake in ProNAi Therapeutics stock. PNC Financial Services Group Inc. bought a new stake in shares of ProNAi Therapeutics, Inc. (NASDAQ:SRRA) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 746,738 shares of the biotechnology company’s stock, valued at approximately $1,142,000. PNC Financial Services Group Inc. owned 1.43% of ProNAi Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 55.72% of the company’s stock.

About ProNAi Therapeutics

Sierra Oncology, Inc, formerly ProNAi Therapeutics, Inc, is a clinical-stage drug development company. The Company’s lead drug candidate, SRA737, is orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1), a key cell cycle checkpoint and central regulator of the deoxyribonucleic acid (DNA) Damage Response (DDR) network.

Receive News & Ratings for ProNAi Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProNAi Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.